[Research] Alteogen (196170) – Daishin Securities | Key US Patent Risks Significantly Eased · New Licensing Catalysts · Keytruda SC Milestones / 2026-06-02
Brokerage : Daishin Securities Analyst : Kahye Hong (RA: Cherry Lee) Investment Rating : BUY (Maintained) Target Price : KRW 500,000 (Maintained) Core Momentum : Favorable outcomes in key US patent proceedings significantly ease IP risks, while discussions with 10+ potential partners under MTAs and surging Keytruda SC sales accelerate recognition of the remaining USD…